TRIALS CURRENTLY OPEN

USON 16176

A Multicenter, Randomized, Double-blind Placebo-controlled Phase 3 Study of Bruton’s Tyrosine Kinas (BTK) Inhibitor, Ibrutinib, in Combination with Rituximb versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

USON 19062

A Phase 1B/3 Randomized, Double-blind, Active-controlled 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)

USON 19084

Waldenstrom’s Lymphoma- Relapsed or Refractory using Zanubritinib

Also See STAR Trials – USOR #11282, #18013